Clinical Trial Results:
A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two FLUAD-like Surface Antigen Adjuvanted with MF59C.1 Influenza Vaccines Containing 7.5 mg or 15 mg of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 mg of A/H5N1 Influenza Antigen, in Adults
Summary
|
|
EudraCT number |
2006-004063-66 |
Trial protocol |
IT |
Global completion date |
10 Jan 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Feb 2016
|
First version publication date |
18 Feb 2016
|
Other versions |
|
Summary report(s) |
V87P2_CTRD |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.